Abstract
Although 75 mg/m2 docetaxel (DTX) with 10 mg prednisolone regimen is a gold standard of the first-line chemotherapy for patients with metastatic castration-resistant prostate cancer (mCRPC), optimal number of the cycles remains controversial. Most guidelines recommend DTX regimen should be terminated up to 10 cycles, but the optimal number is controversial. We retrospectively analyzed 279 CRPC patients who received DTX regimen. Patients having more than 10 cycles of DTX had significantly better overall survival (OS) than those having 10 or less, and prediction model of optimal number of cycles in DTX regimen was constructed based on the risk table employing the combination of three factors (ALP [cutoff 189 IU/L], hemoglobin [11.3 g/dL], and age [65 years] at the start of DTX therapy), and scoring based on the hazard ratio of each risk factor (ALP 4, hemoglobin 2, age 3). The prediction model could effectively predict the probability of the length of DTX therapy, with the c-index of 0.7274. Since the new drugs are clinically available, optimal number of cycles should be determined based on the PS, toxicities, or patients’ wish. Our predicting model may help in patients’ consultation before starting DTX regimen, or in selecting potential patients with intolerant DTX regimen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502–12.
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, Wong YN, Hahn N, Kohli M, Cooney MM, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, Garcia JA, DiPaola RS. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373(8):737–46.
Shimabukuro T, Sakano S, Matsuda K, Kamiryo Y, Yamamoto N, Kaneda Y, Nasu T, Baba Y, Suga A, Yamamoto M, Aoki A, Takai K, Yoshihiro S, Konishi M, Imoto K, Matsuyama H. Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study. Int J Clin Oncol. 2013;18(1):62–7.
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513–20.
Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.
de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R. Association of survival benefit with docetaxel in prostate cancer and total number of cycles administered: a post hoc analysis of the mainsail study. JAMA Oncol. 2017;3(1):68–75.
Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van AN, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16(4):417–25.
Kawahara T, Miyoshi Y, Sekiguchi Z, Sano F, Hayashi N, Teranishi J, Misaki H, Noguchi K, Kubota Y, Uemura H. Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel. PLoS One. 2012;7(10):e48186.
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold L, Berry WR, de Wit R, Eisenberger MA, Tannock IF, Sonpavde G. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61(2):363–9.
Matsuyama H, Shimabukuro T, Hara I, Kohjimoto Y, Suzuki K, Koike H, Uemura H, Hayashi T, Ueno M, Kodaira K, Tomita Y, Sakurai T, Shimizu N. Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer. Int J Clin Oncol. 2014;19(5):946–54.
Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002;20(19):3972–82.
Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232–7.
Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res. 2007;13(21):6396–403.
Armstrong AJ, Garrett-Mayer E, de Wit R, Tannock I, Eisenberger M. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res. 2010;16(1):203–11.
Pond GR, Armstrong AJ, Wood BA, Leopold L, Galsky MD, Sonpavde G. Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int. 2012;110(11 Pt B):E461–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Matsuyama, H. et al. (2018). Prediction of Optimal Number of Cycles in Docetaxel Regimen for Patients with mCRPC. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_35
Download citation
DOI: https://doi.org/10.1007/978-981-10-7013-6_35
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-7012-9
Online ISBN: 978-981-10-7013-6
eBook Packages: MedicineMedicine (R0)